Andrew Rawdin
BSc (ºù«Ӱҵ Hallam), MRes (York)
Population Health, School of Medicine and Population Health
Health Economic Modeller
a.rawdin@sheffield.ac.uk
+44 114 222 0823
+44 114 222 0823
Regent Court (ScHARR)
Full contact details
Andrew Rawdin
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
ºù«Ӱҵ
S1 4DA
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
ºù«Ӱҵ
S1 4DA
- Profile
-
I joined ScHARR in 2006 after gaining a BSc in Mathematics at ºù«Ӱҵ Hallam University and an MRes in Mathematics and Ecology at the University of York.
- Research interests
-
My research interests are:
- Discrete event simulation modelling
- Health economic modelling
- Development of a formal framework for the validation of computer simulation models in health economics
- Economic modelling of Public Health interventions
- Population dynamics modelling in epidemic disease transmission
- Investigation of relationships between long term degenerative diseases and exposure to industrial pollutants.
I am currently working on the following projects:
- Economic effectiveness of pharmaceutical interventions for hepatocellular carcinoma
- The comparative economics effectiveness of different treatment methodologies for renal failure
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- . BMC Psychiatry, 15.
- . PharmacoEconomics, 33(8), 833-847.
- . BMC Psychiatry, 15(1).
- . Public Health, 128(9), 804-810.
- . Value in Health, 13(2), 215-221.
- . Health technology assessment (Winchester, England), 13(2).
- . Health Technology Assessment, 16(20).
- . Health Technology Assessment, 14(25).
- . Health Technology Assessment, 18(17).
- . Health Technology Assessment, 18(16).
All publications
Journal articles
- . npj Digital Medicine, 4.
- . Frontiers in Public Health, 8.
- . Health Technology Assessment, 24(29).
- . Applied Health Economics and Health Policy, 17(3), 295-313.
- . PharmacoEconomics.
- . PharmacoEconomics, 36(7), 759-768.
- . PharmacoEconomics, 36(8), 903-915.
- . Health Technology Assessment, 21(71), 1-258.
- . Journal of Epidemiology and Community Health, 71, 897-904.
- . PharmacoEconomics, 35(8), 805-815.
- . Health Technology Assessment, 20(78), 1-406.
- . BMC Psychiatry, 15.
- . PharmacoEconomics, 33(8), 833-847.
- . BMC Psychiatry, 15(1).
- . Public Health, 128(9), 804-810.
- A review of discrete event simulation in National Coordinating Centre for Health Technology Assessment-funded work and a case study exploring the cost-effectiveness of testing for thrombophilia in patients presenting with an initial idiopathic venous thromboembolism.. J. Simulation, 4, 14-23.
- . Value in Health, 13(2), 215-221.
- . Health technology assessment (Winchester, England), 13(2).
- . Health Technology Assessment, 20(78), 407-424.
- . Health Technology Assessment, 16(20).
- . Health Technology Assessment, 14(25).
- . SN Comprehensive Clinical Medicine.
- . Health Technology Assessment, 19(18), 1-120.
- . Health Technology Assessment, 18(17).
- . Health Technology Assessment, 18(16).
Conference proceedings papers
- . Value in Health, Vol. 17(7) (pp A458-A459)
- Clopidogrel is cost-effective compared with aspirin in United Kingdom patients with a myocardial infarction who subsequently sustain an ischaemic stroke or peripheral arterial disease event. VALUE HEALTH, Vol. 11(3) (pp A194-A195)
Posters
- Assessing the cost of parathyroidectomy as a treatment for uncontrolled secondary hyperparathyroidism in stage 5 chronic kidney disease.
- Cost effectiveness of group art therapy for patients with non-psychotic mental health disorders in England and Wales (2014).
Preprints
- Teaching interests
-
My teaching interests are:
- Supervising MSc dissertation projects
- Professional activities and memberships
-
I am a member of the ScHARR Marketing Committee